AZ Plans To Triple Spending On Russia Drugs Over Next Five Years
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca said it plans to at least triple its current investment in Russia, to as much as $1.2 billion by 2017 to develop new products in targeted drugs, biomarkers, predictive medicine and design of clinical studies.